9/1/2022 7:37:35 AM
Ocugen Appoints Robert Hopkins As Chief Medical Officer
5/23/2022 6:57:19 AM
Ocugen Says FDA Lifts Clinical Hold On Company's Phase 2/3 Clinical Trial, OCU-002, For COVAXIN
4/25/2022 7:37:54 AM
Ocugen Announces Positive DSMB Recommendation For OCU400-101 Clinical Trial
3/23/2022 8:03:02 AM
Ocugen Appoints Marna Whittington To Board
3/4/2022 7:20:00 AM
Ocugen Says FDA Declines EUA For COVAXIN For Active Immunization To Prevent COVID-19 In Ages 2 To 18
2/22/2022 10:12:30 PM
Ocugen Announces Pricing Of $53.5 Mln Public Offering Of Common Stock
12/30/2021 10:06:47 AM
Bharat Biotech Reports Positive Data From COVAXIN, COVID-19 Candidate Vaccine, In Children 2- 18 Yrs
12/9/2021 7:38:25 AM
Ocugen: FDA Accepts IND Application To Begin Phase 1/2 Trial For OCU400 To Treat Inherited Retinal Degeneration